Teaching hospital
Appears in 3 stories · Last updated Oct 21, 2026
Lead sponsor of the RAG-18 Phase I trial
Three boys with Duchenne muscular dystrophy received monthly infusions of an experimental drug. Four months later, muscle biopsies showed 3.5- to 5.3-fold increases in utrophin, a protein that can stand in for the missing dystrophin.
Updated Oct 21
As of September 2026: Lead trial site for the China Phase I/III study
About 1.5 million people worldwide have retinitis pigmentosa, an inherited disease that destroys the retina's light-sensing cells and can end in blindness. The only approved treatment covers patients with a specific RPE65 gene mutation — a small fraction of the affected population.
Updated Sep 29
As of September 2026: Lead site for GENESIS-IPF-3
Insilico Medicine dosed the first patient this week in a Phase III trial of Rentosertib, a drug for the progressive lung disease idiopathic pulmonary fibrosis. It's the first medicine with both an AI-identified target and an AI-designed molecule to reach this stage of testing.
Updated Sep 11
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
